PDL BioPharma Misses Estimates, Offers Revenue Guidance Below Estimates (PDLI)
3/2/2010-Shares of PDL BioPharma (NASDAQ: PDLI) are trading flat after hours Tuesday after the company reported Q4 EPS of $0.17, missing consensus estimates of $0.19.
Revenues for the quarter fell 15% year-over-year to $58.3 million, falling short of consensus estimates of $70.3 million.
The company expects Q1 revenues of $62 million, versus consensus estimates of $70.3 million.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup
